Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Advances in the Diagnosis and Prognosis of Breast Cancer?s Minor Residual Lesions

Weici Liu

Breast cancer’s minor residual lesions post-treatment have posed challenges in accurate diagnosis and prognosis. This article explores recent advancements in the field that have revolutionized the assessment of these lesions. Multipara metric imaging techniques, liquid biopsies, artificial intelligence (AI), genomic profiling, and predictive models are reshaping the landscape of post-treatment management. Multipara metric imaging combines functional and morphological data for precise lesion characterization. Liquid biopsies offer non-invasive monitoring of treatment response and detection of residual cancer cells. AI-driven algorithms analyze imaging and clinical data, aiding in diagnosis and outcome prediction. Genomic profiling identifies genetic alterations influencing residual cancer cell behavior. Predictive models integrate data for recurrence likelihood estimation. While challenges persist, such as standardization and ethical considerations, these innovations hold great promise for personalized medicine and improved patient outcomes